conducted a clinical study of the combined use of FGF-2 and CO3Ap in 10 periodontitis patients with intrabony defect (mean bone defect depth: 5.7 mm) to evaluate the safety and efficacy of such a combination [24]. This evidence concerns the gene FGF2 and periodontitis.